Evidence map›Paper›PMID 29893492›Full record

ArticleHepatology (Baltimore, Md.)2019

An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People.

Sanae Hayashi, Anis Khan, Brenna C Simons, Chriss Homan, Takeshi Matsui, Kenji Ogawa, Keigo Kawashima, Shuko Murakami, Satoru Takahashi, Masanori Isogawa and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Sanae HayashiDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Anis KhanDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Brenna C SimonsLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Chriss HomanLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Takeshi MatsuiCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Kenji OgawaChemical Genetics Laboratory, RIKEN, 2-1 Hirosawa, Wako, Saitama, Japan.
Keigo KawashimaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Shuko MurakamiDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Satoru TakahashiDepartment of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Masanori IsogawaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Kazuho IkeoCenter for Information Biology, National Institute of Genetics, Mishima, Japan.
Masashi MizokamiThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Brian J McMahonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
Yasuhito TanakaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Nagoya City University · JPAlaska Native Tribal Health Consortium · USCenter for Global Health · USNational Institute of Genetics · JPRIKEN · JPTeine Keijinkai Hospital · JP

Funding

Gilead Sciences IN-US-334-2090Japan Agency for Medical Research and Development 17fk0310101h0001Japan Agency for Medical Research and Development JP16fk0310512h0005Japan Agency for Medical Research and Development JP18fk0310101h0002Ministry of Education, Culture, Sports, Science, and Technology 16H05288Ministry of Education, Culture, Sports, Science, and Technology 16K19360Ministry of Health, Labor, and Welfare of Japan H26-Bsou-kanen-ippan-013The Japan Agency for Medical Research and Development 17fk0310101h0001The Japan Agency for Medical Research and Development JP16fk0310512h0005The Japan Agency for Medical Research and Development JP18fk0310101h0002The Ministry of Education, Culture, Sports, Science, and Technology 16H05288The Ministry of Education, Culture, Sports, Science, and Technology 16K19360The Ministry of Health, Labor, and Welfare of Japan H26-Bsou-kanen-ippan-013
6 · The paper itself

Abstract

Hepatitis B virus (HBV) genotype F1b infection is strongly associated with hepatocellular carcinoma (HCC) in young Alaskan Native (AN) people. However, the mechanisms by which genotype F1b causes HCC are unclear. Here, we analyzed the clinical and virological significance of genotype F1b in long-term serial samples from 20 HCC patients with HBV infection. Complete sequence analyses revealed that all isolates were genotype F1b. In the HCC patients, T1938C and A2051C mutations in the core region had accumulated significantly with A1762T/G1764A mutations in the basal core promoter (BCP) region and G1896A mutation in the precore (PC) region. Several HBV clones containing the core mutations were examined for their replication efficiency and core stability in vitro. Clones containing the A2051C mutation replicated more efficiently than the wild type in association with enhanced stability of core protein dimerization. In chimeric mice with human hepatocytes carrying BCP/PC/2051 mutant but not with wild-type virus, liver fibrosis was induced in association with high levels of serum HBV DNA and hepatitis B surface antigen. Interestingly, microarray analysis and validation study showed that five genes associated with cell proliferation or carcinogenesis, v-myc avian myelocytomatosis viral oncogene homolog, Grb2-associated binding protein 2, bradykinin receptor B2, follistatin, and mitogen-activated protein kinase kinase kinase 8, were significantly up-regulated in human hepatocytes infected with genotype F1b, particularly the BCP/PC/2051 mutant, compared with other genotypes. Conclusion: We have identified an association between Alaska-specific core mutations and HCC development in AN people infected with genotype F1b; accumulation of these core mutations during the course of chronic infection with genotype F1b would contribute to HCC development in AN people earlier in life.

Indexed as

GenotypeIndigenous PeoplesAdolescentAdultAgedAlaskaCarcinoma, HepatocellularChildChild, PreschoolHepatitis B, ChronicHepatitis B virusHumansInfantLiver NeoplasmsMiddle AgedMutation

Identifiers

PMID29893492
OpenAlexW2808136611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.